ALPINE IMMUNE SCIENCES INC (ALPN)

Company Profile

Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovery of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. The company is headquartered in Seattle, Washington and currently employs 126 full-time employees. The company went IPO on 2015-06-17. The firm is focused on discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. The firm's scientific platform uses a directed evolution process to convert native immune system proteins from the immunoglobulin super family (IgSF) into multi-targeted therapeutics capable of modulating the human immune system. The Company’s product candidates include ALPN-101, ALPN-202 and ALPN-303. ALPN-101 is a dual inducible T cell costimulator (ICOS) and cluster of differentiation 28 (CD28) antagonist intended for the treatment of autoimmune and inflammatory diseases. Its oncology program is ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor intended for the treatment of cancer. ALPN-303 is a dual B-cell cytokine antagonist for the treatment of B-cell mediated diseases.

Company Info

ALPINE IMMUNE SCIENCES INC

188 East Blaine St., Suite 200

Seattle WASHINGTON 98102

P: 12067884545

CEO: Mitchell H. Gold

Employees: 126

Website: https://www.alpineimmunesciences.com/